Unresectable Renal Cell Carcinoma Recruiting Phase 2 Trials for Axitinib (DB06626)

IndicationStatusPhase
DBCOND0115886 (Unresectable Renal Cell Carcinoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03595124Axitinib and Nivolumab in Treating Patients With Unresectable or Metastatic TFE/Translocation Renal Cell CarcinomaTreatment